1. Home
  2. RFI vs SGHT Comparison

RFI vs SGHT Comparison

Compare RFI & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Total Return Realty Fund Inc.

RFI

Cohen & Steers Total Return Realty Fund Inc.

N/A

Current Price

$11.01

Market Cap

293.3M

Sector

Finance

ML Signal

N/A

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

N/A

Current Price

$8.14

Market Cap

309.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RFI
SGHT
Founded
1992
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.3M
309.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RFI
SGHT
Price
$11.01
$8.14
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$9.08
AVG Volume (30 Days)
79.4K
206.2K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
8.25%
N/A
EPS Growth
N/A
28.16
EPS
N/A
N/A
Revenue
N/A
$77,363,000.00
Revenue This Year
N/A
$11.67
Revenue Next Year
N/A
$10.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.78
$3.19
52 Week High
$12.17
$9.24

Technical Indicators

Market Signals
Indicator
RFI
SGHT
Relative Strength Index (RSI) 29.19 56.69
Support Level $10.86 $8.00
Resistance Level $11.38 $8.80
Average True Range (ATR) 0.13 0.35
MACD -0.04 -0.15
Stochastic Oscillator 0.00 29.36

Price Performance

Historical Comparison
RFI
SGHT

About RFI Cohen & Steers Total Return Realty Fund Inc.

Cohen & Steers Total Return Realty Fund Inc is a diversified closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: